12/16/2025
We’re proud to share that Parexel nominated not one, but two Velocity leaders, Dan Robitaille (US) and Rachel Buck (UK), to serve as mentors in its Emerging Site Scholarship Program for 2025.
Now in its second year, Parexel’s scholarship programme supports early-stage and research-naive sites across the US and Europe, providing dedicated mentoring from experienced research leaders.
This year’s recipients span England, Northern Ireland and multiple US states. Each are in the first five years of operation and are 75% minority owned/operated. They receive structured support to build quality, capacity and long-term sustainability in clinical research.
As Rachel shared, programs like this are essential to strengthening the UK and global research ecosystem: “Building capacity across the UK clinical trial landscape ensures patients have better access, geographically and demographically, to cutting-edge research. Many NHS sites are overloaded, so supporting newer private sites helps reduce bottlenecks, accelerates start-up and recruitment, and ultimately improves the UK’s competitiveness globally.
"Mentorship creates a pipeline of capable sites, strengthens quality standards across the ecosystem, and fosters the partnerships we need for future innovation.”
At Velocity, we believe collaboration is fundamental to the future of clinical trials. By helping emerging sites develop robust processes, stronger community visibility, and operational excellence, we’re contributing to a more resilient and inclusive research landscape; one that benefits sponsors, investigators, and above all, patients.
Congratulations to all this year’s scholarship recipients, and thank you to Parexel for championing site development on a global scale. We’re honored to play a role in shaping the next generation of high-performing research sites.
